Acadian Asset Management LLC Sells 845,036 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Acadian Asset Management LLC reduced its stake in Cellebrite DI Ltd. by 17.7%, selling 845,036 shares and holding approximately 3.9 million shares valued at $76.1 million.
• Institutional investors own 45.88% of Cellebrite DI's stock, with significant increases in stakes reported by firms like Invesco Ltd. and Handelsbanken Fonder AB during the first quarter.
• Recent analyst ratings show a positive trend, with a consensus target price of $22.40 and several firms upgrading their ratings to "buy," despite a lowered price target from some analysts.

Acadian Asset Management LLC trimmed its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 17.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,918,450 shares of the company's stock after selling 845,036 shares during the period. Acadian Asset Management LLC owned 1.64% of Cellebrite DI worth $76,106,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Assetmark Inc. bought a new position in shares of Cellebrite DI during the first quarter valued at $33,000. Catalyst Capital Advisors LLC purchased a new position in shares of Cellebrite DI in the 1st quarter worth $51,000. Virtus Advisers LLC purchased a new position in Cellebrite DI in the first quarter worth about $63,000. Advisors Asset Management Inc. increased its position in shares of Cellebrite DI by 24.7% during the 1st quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock valued at $119,000 after purchasing an additional 1,214 shares during the last quarter. Finally, JT Stratford LLC purchased a new position in shares of Cellebrite DI in the first quarter worth approximately $209,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Trading Up 2.8%

Shares of NASDAQ:CLBT traded up $0.47 during midday trading on Monday, reaching $17.27. 634,046 shares of the company were exchanged, compared to its average volume of 1,699,003. The stock has a market cap of $4.13 billion, a PE ratio of -22.70, a price-to-earnings-growth ratio of 3.05 and a beta of 1.28. The business's fifty day moving average is $15.18 and its two-hundred day moving average is $16.95. Cellebrite DI Ltd. has a one year low of $13.10 and a one year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. During the same quarter in the prior year, the firm earned $0.10 EPS. The business's revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CLBT shares. Lake Street Capital dropped their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Needham & Company LLC lowered their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Finally, Wall Street Zen lowered Cellebrite DI from a "buy" rating to a "hold" rating in a report on Saturday. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.